Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3

MT Newswires Live

May 22, 2025

Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.

The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.

The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.

A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.

Shares of the company were up over 5.4% in recent Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537945754"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537945754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537945754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537945754","market":"sh","top_or_hot":-1,"title":"Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3","media":"MT Newswires Live","content":"<html><body><p> Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.</p><p>The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.</p><p>The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.</p><p>A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.</p><p>Shares of the company were up over 5.4% in recent Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInstil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-22 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.</p><p>The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.</p><p>The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.</p><p>A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.</p><p>Shares of the company were up over 5.4% in recent Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIL","symbol_name":"Instil Bio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537945754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537945754","pubTimestamp":1747915391,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Instil Bio  and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.Shares of the company were up over 5.4% in recent Thursday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIL":"Instil Bio, Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技","SSI":"Stage Stores Inc"},"translate_title":"Instil Bio和ImmuneOnco表示肺癌药物`2510中期试验有望于第三季度在中国进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIL":1,"SSI":1},"content_text":"Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.Shares of the company were up over 5.4% in recent Thursday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}